165 related articles for article (PubMed ID: 15634274)
21. Role of zymogen and activated factor X as scaffolds for the inhibition of the blood coagulation factor VIIa-tissue factor complex by recombinant nematode anticoagulant protein c2.
Bergum PW; Cruikshank A; Maki SL; Kelly CR; Ruf W; Vlasuk GP
J Biol Chem; 2001 Mar; 276(13):10063-71. PubMed ID: 11139576
[TBL] [Abstract][Full Text] [Related]
22. Activity and regulation of factor VIIa analogs with increased potency at the endothelial cell surface.
Ghosh S; Ezban M; Persson E; Pendurthi U; Hedner U; Rao LV
J Thromb Haemost; 2007 Feb; 5(2):336-46. PubMed ID: 17092304
[TBL] [Abstract][Full Text] [Related]
23. Residues of the 39-loop restrict the plasma inhibitor specificity of factor IXa.
Yang L; Rezaie AR
J Biol Chem; 2013 May; 288(18):12692-8. PubMed ID: 23530052
[TBL] [Abstract][Full Text] [Related]
24. Surface plasmon resonance studies of the interaction between factor VII and tissue factor. Demonstration of defective tissue factor binding in a variant FVII molecule (FVII-R79Q).
O'Brien DP; Kemball-Cook G; Hutchinson AM; Martin DM; Johnson DJ; Byfield PG; Takamiya O; Tuddenham EG; McVey JH
Biochemistry; 1994 Nov; 33(47):14162-9. PubMed ID: 7947828
[TBL] [Abstract][Full Text] [Related]
25. Recent estimates of the structure of the factor VIIa (FVIIa)/tissue factor (TF) and factor Xa (FXa) ternary complex.
Lee CJ; Chandrasekaran V; Wu S; Duke RE; Pedersen LG
Thromb Res; 2010 Apr; 125 Suppl 1():S7-S10. PubMed ID: 20156644
[TBL] [Abstract][Full Text] [Related]
26. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
Hoffman M; Monroe DM
Dis Mon; 2003 Jan; 49(1):14-21. PubMed ID: 12525825
[TBL] [Abstract][Full Text] [Related]
27. An all-atom solution-equilibrated model for human extrinsic blood coagulation complex (sTF-VIIa-Xa): a protein-protein docking and molecular dynamics refinement study.
Venkateswarlu D; Duke RE; Perera L; Darden TA; Pedersen LG
J Thromb Haemost; 2003 Dec; 1(12):2577-88. PubMed ID: 14750502
[TBL] [Abstract][Full Text] [Related]
28. A frequent human coagulation Factor VII mutation (A294V, c152) in loop 140s affects the interaction with activators, tissue factor and substrates.
Toso R; Pinotti M; High KA; Pollak ES; Bernardi F
Biochem J; 2002 Apr; 363(Pt 2):411-6. PubMed ID: 11931672
[TBL] [Abstract][Full Text] [Related]
29. Role of the N-terminal EGF module of coagulation factor IX in activation of factors IX and X.
Persson KE
Scand J Clin Lab Invest Suppl; 2002; 237():13-8. PubMed ID: 12570162
[TBL] [Abstract][Full Text] [Related]
30. Synthetic peptide analogs of tissue factor and factor VII which inhibit factor Xa formation by the tissue factor/factor VIIa complex.
Rønning HF; Risøen UC; Orning L; Sletten K; Sakariassen KS
Thromb Res; 1996 Oct; 84(2):73-81. PubMed ID: 8897697
[TBL] [Abstract][Full Text] [Related]
31. The effect of O-fucosylation on the first EGF-like domain from human blood coagulation factor VII.
Kao YH; Lee GF; Wang Y; Starovasnik MA; Kelley RF; Spellman MW; Lerner L
Biochemistry; 1999 Jun; 38(22):7097-110. PubMed ID: 10353820
[TBL] [Abstract][Full Text] [Related]
32. Residues 88-109 of factor IXa are important for assembly of the factor X activating complex.
Wilkinson FH; London FS; Walsh PN
J Biol Chem; 2002 Feb; 277(8):5725-33. PubMed ID: 11726655
[TBL] [Abstract][Full Text] [Related]
33. Role of the N-terminal epidermal growth factor-like domain of factor X/Xa.
Kittur FS; Manithody C; Rezaie AR
J Biol Chem; 2004 Jun; 279(23):24189-96. PubMed ID: 15069066
[TBL] [Abstract][Full Text] [Related]
34. Molecular determinants involved in differential behaviour between soluble tissue factor and full-length tissue factor towards factor VIIa.
Prasad R; Sen P
Phys Chem Chem Phys; 2017 Aug; 19(33):22230-22242. PubMed ID: 28799584
[TBL] [Abstract][Full Text] [Related]
35. Zn²(+) -containing protein S inhibits extrinsic factor X-activating complex independently of tissue factor pathway inhibitor.
Fernandes N; Mosnier LO; Tonnu L; Heeb MJ
J Thromb Haemost; 2010 Sep; 8(9):1976-85. PubMed ID: 20492471
[TBL] [Abstract][Full Text] [Related]
36. Direct inhibition of factor VIIa by TFPI and TFPI constructs.
Peraramelli S; Thomassen S; Heinzmann A; Rosing J; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M
J Thromb Haemost; 2013 Apr; 11(4):704-14. PubMed ID: 23347185
[TBL] [Abstract][Full Text] [Related]
37. Structure-function relationships in factor IX and factor IXa.
Schmidt AE; Bajaj SP
Trends Cardiovasc Med; 2003 Jan; 13(1):39-45. PubMed ID: 12554099
[TBL] [Abstract][Full Text] [Related]
38. Structural requirements for the interaction between tissue factor and factor VII: characterization of chymotrypsin-derived tissue factor polypeptides.
O'Brien DP; Anderson JS; Martin DM; Byfield PG; Tuddenham EG
Biochem J; 1993 May; 292 ( Pt 1)(Pt 1):7-12. PubMed ID: 8503864
[TBL] [Abstract][Full Text] [Related]
39. Penthalaris, a novel recombinant five-Kunitz tissue factor pathway inhibitor (TFPI) from the salivary gland of the tick vector of Lyme disease, Ixodes scapularis.
Francischetti IM; Mather TN; Ribeiro JM
Thromb Haemost; 2004 May; 91(5):886-98. PubMed ID: 15116248
[TBL] [Abstract][Full Text] [Related]
40. Formation of factors IXa and Xa by the extrinsic pathway: differential regulation by tissue factor pathway inhibitor and antithrombin III.
Lu G; Broze GJ; Krishnaswamy S
J Biol Chem; 2004 Apr; 279(17):17241-9. PubMed ID: 14963035
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
